Allogene Cellectis Agreement

10 Sep

Allogeneic CAR-T therapies are developed from healthy donor cells and are stored “from the bar” for use in patients. This approach eliminates the need to develop a personalized therapy from a patient`s own cells, facilitates manufacturing, and reduces the time patients have to wait for CAR-T treatment. The allogeneic portfolio includes 16 preclinical T-cell therapy active ingredients and UCART19, an allogeneic car-T therapy currently in Phase 1 development for the treatment of acute lymphatic leukemia (LL). Through its remarkable partnerships, Allogene uses breakthrough technology platforms, including TALEN® gene editing technology, to advance its portfolio of immunonkological therapies.

Posted By

Posted Sep 10th, 2021

Comments are closed

Enter your Comment

 

 

Fellows

2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003

News about partners